ES2146192T1 - Metodo y composiciones para modular la sensibilidad a los corticosteroides. - Google Patents

Metodo y composiciones para modular la sensibilidad a los corticosteroides.

Info

Publication number
ES2146192T1
ES2146192T1 ES98912929T ES98912929T ES2146192T1 ES 2146192 T1 ES2146192 T1 ES 2146192T1 ES 98912929 T ES98912929 T ES 98912929T ES 98912929 T ES98912929 T ES 98912929T ES 2146192 T1 ES2146192 T1 ES 2146192T1
Authority
ES
Spain
Prior art keywords
agent
corticosteroid
subject
inhibitor
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES98912929T
Other languages
English (en)
Inventor
Les Sekut
Adam Carter
Tariq Ghayur
Subhashis Banerjee
Daniel E Tracey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/820,692 external-priority patent/US6054487A/en
Application filed by BASF SE filed Critical BASF SE
Publication of ES2146192T1 publication Critical patent/ES2146192T1/es
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a un procedimiento para modular la sensibilidad a los corticoesteroides en un sujeto. Conforme a este procedimiento, se administra a dicho sujeto un agente que se opone a una diana que regula la producción de IFN-{ga}, así como un corticoesteroide de manera que la sensibilidad del sujeto al corticoesteroide se modula en comparación con lo que es cuando el corticoesteroides se administra solo. Según una realización, dicho agente es un antagonista de IL-8. Según otra realización, dicho agente es un antagonista de la interleuquina-12 (IL-12). Según otra realización más, el agente es un antagonista de las células NJ. Según una realización preferente, el agente es un inhibidor de una proteasa de la familia de las caspasas, preferentemente un inhibidor de la enzima de conversión de la interleuquina -1''beta'' (ICE). En otras realizaciones preferentes, el agente es un anticuerpo monoclonal anti-IL-12 o un anticuerpo anti-asialo-GM1 o un anticuerpo MK1.1. Otros agentes preferentes comprenden los inhibidores de fosfodiesterasa IV y beta-2 agonistas. Los procedimientos de esta invenciones revelan útiles para el tratamiento de una pluralidad de enfermedades y trastornos inflamatorios e inmunológicos. Esta invención se refiere también a composiciones farmacéuticas que comprenden un agente que se opone a una diana que regula la producción de IFN-''gamma'' en un sujeto, a un corticoesteroide y a un excipiente farmacéuticamente aceptable. Una composición comprende un inhibidor de ICE, un corticoesteroide y un excipiente farmacéuticamente aceptable.
ES98912929T 1997-03-18 1998-03-12 Metodo y composiciones para modular la sensibilidad a los corticosteroides. Pending ES2146192T1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/820,692 US6054487A (en) 1997-03-18 1997-03-18 Methods and compositions for modulating responsiveness to corticosteroids
US1634698A 1998-01-30 1998-01-30

Publications (1)

Publication Number Publication Date
ES2146192T1 true ES2146192T1 (es) 2000-08-01

Family

ID=26688484

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98912929T Pending ES2146192T1 (es) 1997-03-18 1998-03-12 Metodo y composiciones para modular la sensibilidad a los corticosteroides.

Country Status (20)

Country Link
EP (1) EP0998300A1 (es)
JP (1) JP2002504091A (es)
KR (1) KR20000076420A (es)
CN (1) CN1269722A (es)
AU (1) AU734756B2 (es)
BG (1) BG103808A (es)
BR (1) BR9810409A (es)
CA (1) CA2282845A1 (es)
DE (1) DE998300T1 (es)
ES (1) ES2146192T1 (es)
HU (1) HUP0104439A3 (es)
ID (1) ID22975A (es)
IL (1) IL131815A0 (es)
NO (1) NO994506L (es)
NZ (1) NZ337769A (es)
PL (1) PL336464A1 (es)
SI (1) SI20110A (es)
SK (1) SK122199A3 (es)
TR (1) TR199902615T2 (es)
WO (1) WO1998041232A2 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6706264B1 (en) 1994-03-14 2004-03-16 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
AR015966A1 (es) * 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
CA2276420A1 (en) * 1997-10-31 1999-05-14 Terry Strom Use of anti-il-12 antibodies in transplantation rejection
EP1516630A3 (en) * 1997-10-31 2006-05-03 Wyeth Use of anti-il-12 antibodies in transplantation rejection
WO1999025737A1 (en) * 1997-11-19 1999-05-27 Tanox Pharma B.V. Compositions and methods for treatment of autoimmune diseases, using a monoclonal antibody to the interleukin-12 beta2-chain
KR20010041905A (ko) * 1998-03-16 2001-05-25 시토비아 인크. 디펩티드 카스파제 억제제 및 이의 용도
EP1140206A4 (en) * 1998-11-27 2002-04-10 Technion Res & Dev Foundation VACCINE BASED ON INTERFERON GAMMA INDUCING FACTOR AND ITS USE FOR OBTAINING VACCINE PROTECTION AGAINST MULTIPLE Sclerosis.
DE69927520T2 (de) * 1998-12-09 2006-06-22 Protein Design Labs, Inc., Fremont Verwendung von il-12 antikörpern zur behandlung von psoriasis
AU3876600A (en) 1999-03-16 2000-10-04 Cytovia, Inc. Substituted 2-aminobenzamide caspase inhibitors and the use thereof
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
DE19915465A1 (de) * 1999-04-06 2000-10-19 Apotech Res & Dev Ltd Verwendung eines Caspase-Inhibitors zur Proliferationshemmung von Zellen und Verwendung eines oder mehrerer Caspase-Inhibitors/en zur Behandlung von Erkrankungen beruhend auf Lymphozyten-Hyperproliferation oder zur Suppression einer Immunantwort durch Lymphozyten
US6355618B1 (en) 1999-04-09 2002-03-12 Cytovia, Inc. Caspase inhibitors and the use thereof
IL131047A0 (en) * 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
US6495522B1 (en) 1999-08-27 2002-12-17 Cytovia, Inc. Substituted alpha-hydroxy acid caspase inhibitors and the use thereof
WO2001019373A2 (en) * 1999-09-17 2001-03-22 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
CA2399148A1 (en) 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
AU2001275228A1 (en) * 2000-06-06 2001-12-17 Glaxo Group Limited Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor
WO2001097815A2 (de) * 2000-06-22 2001-12-27 Willy Ben Moussa Ben Mohammed Verwendung von glukokortikosteroiden zur herstellung eines medikamentes für die behandlung von haarschwund
US20020025317A1 (en) * 2000-07-20 2002-02-28 Schering Ag Bispecific monoclonal antibodies to IL-12 and IL-18
AU2000270300A1 (en) * 2000-09-13 2002-03-26 Isis Innovation Limited Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
EP1199074A1 (en) * 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
EP1188438A1 (en) * 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
CN1326562C (zh) * 2001-01-29 2007-07-18 应用研究系统Ars股份公司 Il－18抑制剂制造治疗和/或预防心脏病的药物的应用
EP1425028B1 (en) * 2001-05-16 2009-12-16 Yeda Research And Development Co. Ltd. Use of il-18 inhibitors for the treatement or prevention of sepsis
EP2295081B1 (en) 2001-06-26 2018-10-31 Amgen Inc. Antibodies to OPGL
NZ532310A (en) * 2001-10-05 2007-02-23 Combinatorx Inc Combinations comprising a tetra-substituted pyrimidopyrimidine and a corticosteroid for the treatment of immunoinflammatory disorders
JP2003342196A (ja) * 2002-05-31 2003-12-03 Mukku:Kk 静脈注射用組成物、その製造法およびその製剤
AU2003299196A1 (en) * 2002-09-24 2004-04-23 Combinatorx, Incorporated Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
AU2003263717A1 (en) * 2002-09-25 2004-04-19 Astrazeneca Ab A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
WO2004067006A1 (en) * 2003-01-27 2004-08-12 Pharmacia Corporation Combination of a pde iv inhibitor and a tnf-alpha antagonist
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
WO2005110450A1 (ja) * 2004-05-17 2005-11-24 Keio University 医薬組成物及び治療方法
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AU2005264453B2 (en) 2004-07-16 2011-07-14 Atsuo Sekiyama IL-18 receptor antagonist and pharmaceutical composition containing the antagonist
CA2584169A1 (en) * 2004-10-13 2006-04-20 Kyowa Hakko Kogyo Co., Ltd. Remedies/preventives for chronic skin disease
CA2615173C (en) 2005-07-14 2012-01-03 Lipothera, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
JP2010506941A (ja) * 2006-10-17 2010-03-04 リセラ，インク． 甲状腺眼症の治療のための方法、組成物及び製剤
KR20090100461A (ko) 2007-01-16 2009-09-23 아보트 러보러터리즈 건선의 치료방법
RU2476442C2 (ru) 2007-03-29 2013-02-27 Эббот Лэборетриз Кристаллические антитела против il-12 человека
WO2009117289A2 (en) 2008-03-18 2009-09-24 Abbott Laboratories Methods for treating psoriasis
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
UA111822C2 (uk) 2010-11-24 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Новамедіка" Монотерапевтичий препарат селективного ліпофільного бета-агоніста тривалої дії і спосіб косметичного лікування ожиріння і контурного випинання
WO2015063669A1 (en) 2013-10-30 2015-05-07 Wockhardt Limited Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof
US12102622B2 (en) 2021-02-10 2024-10-01 Iolyx Therapeutics, Inc. Methods for ophthalmic delivery of roflumilast
WO2023049809A1 (en) * 2021-09-22 2023-03-30 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases
WO2024215900A2 (en) * 2023-04-12 2024-10-17 The Board Of Trustees Of The University Of Illinois Agonists of small heterodimer partner for cancer therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320125A (en) * 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
JP3042866B2 (ja) * 1989-09-08 2000-05-22 グラクソ・グループ・リミテッド 呼吸疾患治療薬
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
MX9304585A (es) * 1992-07-31 1994-03-31 Glaxo Group Ltd Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
TR199701170T1 (xx) * 1995-04-14 1998-02-21 Glaxo Wellcome Inc. Beklometazon dipropionat i�in �l��lm�� doz inhaleri.

Also Published As

Publication number Publication date
NO994506D0 (no) 1999-09-17
ID22975A (id) 1999-12-23
JP2002504091A (ja) 2002-02-05
BG103808A (en) 2000-07-31
BR9810409A (pt) 2000-08-22
AU6760498A (en) 1998-10-12
PL336464A1 (en) 2000-06-19
KR20000076420A (ko) 2000-12-26
CA2282845A1 (en) 1998-09-24
TR199902615T2 (xx) 2000-03-21
IL131815A0 (en) 2001-03-19
EP0998300A1 (en) 2000-05-10
SI20110A (sl) 2000-06-30
HUP0104439A2 (hu) 2002-04-29
CN1269722A (zh) 2000-10-11
SK122199A3 (en) 2000-12-11
NO994506L (no) 1999-11-17
DE998300T1 (de) 2001-03-01
WO1998041232A2 (en) 1998-09-24
NZ337769A (en) 2002-09-27
HUP0104439A3 (en) 2002-08-28
AU734756B2 (en) 2001-06-21
WO1998041232A3 (en) 2000-10-05

Similar Documents

Publication Publication Date Title
ES2146192T1 (es) Metodo y composiciones para modular la sensibilidad a los corticosteroides.
AR025669A1 (es) Metodos y composiciones para la modulacion de la capacidad de respuesta a los corticosteroides.
Hayami et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model
Clark et al. The measurement of collagenase, tissue inhibitor of metalloproteinases (timp), and collagenase—timp complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis
Walakovits et al. Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury
Strickland et al. Studies on the role of plasminogen activator in ovulation. In vitro response of granulosa cells to gonadotropins, cyclic nucleotides, and prostaglandins.
Demirag et al. Enhancement of tendon-bone healing of anterior cruciate ligament grafts by blockage of matrix metalloproteinases
Buckley et al. Mast cell subpopulations in the synovial tissue of patients with osteoarthritis: selective increase in numbers of tryptase‐positive, chymase‐negative mast cells
Gelberman et al. Dupuytren's contracture. An electron microscopic, biochemical, and clinical correlative study.
Thompson Jr An experimental study of surface injury to articular cartilage and enzyme responses within the joint.
Dunn et al. Therapeutic modification of nuclear factor (kappa) B binding activity and tumor necrosis factor-alpha gene expression during acute biliary pancreatitis
Ellis et al. The prevention of collagen breakdown in bovine nasal cartilage by TIMP, TIMP-2 and a low molecular weight synthetic inhibitor
Tabassi et al. The type II collagen fragments Helix-II and CTX-II reveal different enzymatic pathways of human cartilage collagen degradation
Woessner Jr Purification of cathepsin D from cartilage and uterus and its action on the protein-polysaccharide complex of cartilage
Goltzman et al. Molecular basis of the spectrum of skeletal complications of neoplasia
EHRLICH et al. Biochemical and physiological events during closure of the stapled distal femoral epiphyseal plate in rats
Awerbuch et al. Morton's metatarsalgia due to intermetatarsophalangeal bursitis as an early manifestation of rheumatoid arthritis.
ATE310019T1 (de) Citrullin-enthaltende fibrin-derivate und ihre verwendung zur diagnose und behandlung von rheumatischer arthritis
Szomor et al. Appearance of calpain correlates with arthritis and cartilage destruction in collagen induced arthritic knee joints of mice.
Rath et al. Synthesis of interleukin-1-like activity by normal rat chondrocytes in culture
Kawahara et al. The 26 S proteasome is activated at two points in the ascidian cell cycle
Kim et al. Osteoprotegerin inhibits in vitro mouse osteoclast formation induced by joint fluid from failed total hip arthroplasty
Salamonsen et al. Production of matrix metalloproteinase 3 (stromelysin) by cultured ovine endometrial cells
NO963497L (no) Fibrin-spesifikt antistoff for anvendelse som et antitrombotisk middel
Tanaka et al. Joint Degradation in a Monkey Model of Collagen‐Induced Arthritis: Role of Cathepsin K Based on Biochemical Markers and Histological Evaluation